Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.51 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887130 | 0.81 | CREBBP (0.55) | HTTPOLBCREBBPKDM4EALDH1A1 | |
| SCHEMBL1333179 | 0.81 | HTT (0.54) | HTTPOLBCREBBPKDM4EALDH1A1 | |
| SCHEMBL8530588 | 0.81 | KDM4E (0.41) | HTTPOLBKDM4EALDH1A1HPGD | |
| SCHEMBL8528867 | 0.80 | KMT2A (0.43) | POLBCREBBPKDM4EALDH1A1HPGD | |
| SCHEMBL8076272 | 0.80 | KMT2A (0.67) | POLBKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4207590 | 0.79 | CREBBP (0.63) | HTTPOLBCREBBPKDM4EALDH1A1 | |
| SCHEMBL29037094 | 0.79 | NOTUM (0.62) | HTTPOLBCREBBPKDM4EALDH1A1 | |
| SCHEMBL13806317 | 0.79 | POLB (0.54) | HTTPOLBCREBBPKDM4EALDH1A1 | |
| SCHEMBL26170754 | 0.79 | HTT (0.53) | HTTPOLBCREBBPKDM4EALDH1A1 | |
| SCHEMBL6545593 | 0.79 | HTT (0.49) | HTTPOLBCREBBPKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| US-6881727-B2 | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | SHIONOGI & CO., LTD. (JP) | 2005-04-19 | — | — | US | claimed |
| EP-1486207-A2 | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | SHIONOGI & CO., LTD. (JP) | 2004-12-15 | — | — | EP | claimed |
| US-20030225043-A1 | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | SHIONOGI & CO., LTD. | 2003-12-04 | — | — | US | claimed |
| US-20030139379-A1 | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | SHIONOGI & CO., LTD. | 2003-07-24 | — | — | US | claimed |
| EP-0950656-A1 | SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 1999-10-20 | — | — | EP | claimed |
| US-20240115626-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11801273-B2 | Compositions and methods to increase production of isothiocyanates | CHURCH & DWIGHT CO., INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023133494-A2 | OIL-BASED ISOTHIOCYANATE PRODUCTS AND PROCESSES FOR PREPARING OIL-BASED ISOTHIOCYANATE PRODUCTS | BRASSICA PROTECTION PRODUCTS LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20220193152-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-10716778-B2 | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals | Veijlen (CW) | 2020-07-21 | — | — | US | disclosed |
| US-6150394-A | 1-(INDOLYL),1-((PHENYL)PHENYL)SULFONAMIDO)ACETIC ACID OR N-HYDROXYACETAMIDE AND DERIVATIVES; ENZYME INHIBITORS E.G., GELATINASE, STROMELYSIN, COLLAGENASE; OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CORNEAL ULCERATION, PERIODONTITIS, HIV | SHIONOGI & CO., LTD. (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-0950656-A1 | SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 1999-10-20 | — | — | EP | disclosed |
| EP-0460679-B1 | Endothelin antagonistic peptide derivatives | BANYU PHARMA CO LTD (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5691315-A | CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5470833-A | Vasodilators, bronchodilators | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| US-5444152-A | Vasolidator or bronchodilator | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139379-A1 | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | MMP9, MMP2, MMP1 | HTT 4143/4885POLB 1884/4885CREBBP 3058/4885 |
| US-20030225043-A1 | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | MMP9, MMP2, MMP1 | HTT 4143/4885POLB 1884/4885CREBBP 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.